FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

NEXT STORY
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
PREV STORY
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

INC Research Launches Catalyst Program to Strengthen Collaboration With Clinical Research Sites, Enhance Delivery to Customers

RALEIGH, N.C., Feb. 17, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a ...

author_avatar
NASDAQ Market News

ePlus and Garrett Regional Medical Center Create Hospital without Walls

HERNDON, Va., Jan. 04, 2017 (GLOBE NEWSWIRE) -- ePlus inc. (NASDAQ:PLUS) today announced that ...

author_avatar
NASDAQ Market News

TiGenix Submits Day 120 Responses to European Medicines Agency for Cx601 Marketing Authorization

PRESS RELEASE TiGenix Submits Day 120 Responses to European Medicines Agency for Cx601 Marketing ...

author_avatar
NASDAQ Market News